Новые возможности снижения сердечно-сосудистого риска в Российской Федерации
Аннотация
VIII Евразийский конгресс кардиологов. Обзор симпозиумов. Новые возможности снижения сердечно-сосудистого риска в Российской Федерации. Системные гипертензии.
Об авторах
О. Д. Остроумова
ФГБУ «НМИЦ кардиологии» Минздрава России
Россия
Россия
Игорь Владимирович Сергиенко
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России
Россия
Россия
Ю. В. Жернакова
Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии» Минздрава России
Россия
Россия
Список литературы
1. Kannel WB et al. 1971
2. Rutan GH et al. 1988
3. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355 (9207): 865-72. DOI: 10.1016/s0140-6736(99)07330-4
4. Neaton JD et al. JAMA 1993
5. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021-104. DOI: 10.1093/eurheartj/ehy339
6. Российские рекомендации по лечению артериальной гипертензии. 2019
7. Chudek J. Ocena profilu bezpieczeństwa stosowania produktu EgiramlonRwpopulacji polskich pacjentów (EG/NT/2012/018) - edycje 1-5 ŚWIAT MEDYCYNY I FARMACJI 84 KWIECIEŃ 2015
8. ASCOT study (Anglo-Scandinavian Cardiac Outcomes Trial). 2005
9. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97
10. VALUE study
11. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurence of clinical events. PREVENT Investigatiors. Circulation 2000; 102: 1503-10
12. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med 2000; 342:145-53
13. AIREX study
14. MICROHOPE study
15. SECURE study
16. ASCOT-BPLA study
17. Opie et al. Drug Heart 1991
18. White WB, Viadero JJ, Lane TJ et al. Effects of combination therapy with captopnil and nifedipine in severe or resistant hypertension. Clin Pharmacol Ther 1986; 39: 43-8
19. Gustrafsson J Cardiovasc Phar 1987; 10 (Suppl. 1): 21-31
20. Кътова Ц., Симова Я., Костова В. Антихпертензивна ефективност Egiramlon - ефекти във времето. Кардио D Брой. 2015; 3: 4-6
21. Tomsсany J et al. RAMONA study Hypertonia es Nephrologia 2013; 17 (2): 49-96
22. Tomsсany J et al. RAMSES study Hypertonia es Nephrologia 2013; 19 (5-6): 15-21
23. Olszanecka-Glinianowicz M, Smertka M, Almgren-Rachtan A et al. Ramipril/amlodipine single pill - Effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status. Pharmacol Rep 2014; 66: 1043-9
24. Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П. и др. Изучение приверженности терапии у пациентов с метаболическим синдромом на примере нового комбинированного антигипертензивного препарата рамиприла и амлодипина по результатам наблюдательного исследования ГРАНАТ-1. Кардиоваскулярная терапия и профилактика. 2017: 16 (1)
25. Марцевич С. Ю., Лукина Ю. В., Кутишенко Н. П. и др. Изучение параметров переносимости и приверженности к терапии у пациентов с хронической обструктивной болезнью легких и артериальной гипертонией на фоне лечения фиксированной комбинацией рамиприла и амлодипина (по результатам наблюдательного исследования «Гранат-2»). Рациональная фармакотерапия в кардиология. 2017: 13 (2)
26. ONTARGET study
27. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients. N Engl J Med 2000; 342: 154-60
28. Verdecchia P, Porcellati C, Reboldi G et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104 (17): 2039-44
29. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 1002; 359 (9311): 995-1003
30. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115 (1): 41-6
31. Dzau VJ, Bernstein K, Celermajer D et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (9A): 1L-20L
32. Agabiti-Rosei E, Ambrosioni E, dal Palu C et al., on behalf of the RACE Study Group: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular hypertrophy in hypertension: results of the RACE (Ramipril Cardioprotective Evaluation) study. J Hypertens 1995; 13: 1325-34
33. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-63
34. Willoughby SR, Rajendran S, Chan WP. Ramipril Sensitizes Platelets to Nitric Oxide. J Am College Cardiol 2012; 60 (10): 887-94
35. Simonyi G, Ferenci T, Finta E. Fixed combinations of renin-angiotensin-aldosterone system inhibitors and calcium channel blockers in relation of patients adherence in hypertension. Eur Heart J 2018; 39 (Suppl.): 398
36. Franse LV, Pahor M, Di Bari M et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18 (8): 1149-54
37. Lehto S, Niskanen L, Ronnemaa T et al. Serum Uric Acid Is a Strong Predictor of Stroke in Patients With Non Insulin-Dependent Diabetes Mellitus. Stroke 1998; 29 (3): 635-9
38. Ежов М.В., Сергиенко И.В., Кухарчук В.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. 2020
39. Neumann FJ, Sousa-Uv M, Ahlsson A et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40 (2): 87-165
40. Kotseva K, De Backer G, De Bacquer D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. ESC Congress, Munich 2018. Eur J Prev Cardiol 2019; 26 (8): 824-35
41. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92 (2): 152-60
42. Wolffenbuttel BH, Franken AA, Vincent HH. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL study. J Intern Med 2005; 257 (6): 531-9
43. Clearfield M, Kallend D, Palmerz M. W16-P-014 Efficacy and safety of rosuvastatin 10 MG versus atorvastatin 20 MG: Results of the pulsar study. Atherosclerosis Supplements. 2005; 6(1): 104
44. Schuster H, Barter PJ, Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-12
45. Pitt B, Loscalzo J, Yčas J et al. Lipid levels after acute coronary syndromes. J Am College Cardiol 2008; 51 (15): 1440-5
46. Nicholls SJ, Brandrup-Wognsen G, Palmer M et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010; 105 (1): 69-76
47. William S, Weintraub WS. Perspective on Trends in Statin Use. JAMA Cardiology 2017; (1): 11-2
48. Redelmeier DA, Manzoor F, Thiruchelvam D. Association Between Statin Use and Risk of Dementia After a Concussion. JAMA Neurology 2019; 76 (8): 887-96
49. Wingo TS, Cutle DJ, Wingo AP et al. Association of Early-Onset Alzheimer Disease With Elevated Low-density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB. JAMA Neurology 2019; 76 (7): 809-17
50. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Eng J Med 2015; 372 (25): 2387-97
51. Шальнова С.А., Деев А.Д., Артамонова Г.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014; 10 (2): 153-9
52. Zhu Y, Pandya BJ, Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63 (10): 3136-41
53. Bickel C, Rupprecht HJ, Blankenberg S et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89 (1): 12-7
54. Wong KYK, Macwalter RS, Fraser HW et al. Struthers, Urate predicts subsequent cardiac death in stroke survivors, Eur Heart J 2002; 23 (10): 788-93
55. Borghi C, Tykarski A, Widecka K et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J 2018; 25 (5): 545-64
56. Чазова И.Е., Жернакова Ю.В., Кисляк О.А. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019; 16 (4): 8-21. DOI: 10.26442/2075082X.2019.4.190686
57. Hui M, Carr A, Cameron S et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford) 2017; 56 (7): e1-e20
58. Butler R, Morri AD, Belch JJF et al. Allopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics With Mild Hypertension. Hypertension 2002; 35 (3): 746-51
59. Farquharson CAJ, Butler R, Hill A et al. Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure. Circulation 2002; 106 (2): 221-6
60. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300 (8): 924-32
61. MacIsaac RL, Salatzki J, Higgins P et al. Allopurinol and Cardiovascular Outcomes in Adults With Hypertension. Hypertension 2016; 67 (3): 535-40
62. Bredemeier M, Lopes LM, Eisenreich MA et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2018; 18: 24
63. White WB, Sa KG, Becker MA et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Eng J Med 2018; 378 (13): 1200-10
Рецензия
Для цитирования:
Остроумова О.Д., Сергиенко И.В., Жернакова Ю.В. Новые возможности снижения сердечно-сосудистого риска в Российской Федерации. Системные гипертензии. 2020;17(2):91-97. https://doi.org/10.26442/2075082X.2020.2.200237
For citation:
Ostroumova O.D., Sergienko I.V., Zhernakova Yu.V. New opportunities for reducing cardiovascular risk in the Russian Federation. Systemic Hypertension. 2020;17(2):91-97. (In Russ.) https://doi.org/10.26442/2075082X.2020.2.200237
Просмотров: 3
Послать статью по эл. почте 